Multiple Endpoints in Clinical Trials

On 21 October 2022 the FDA published the final guidance on multiple endpoints in clinical trials for industry.

This guidance provides sponsors and review staff with the Agency’s thinking about the problems posed by multiple endpoints in the analysis and interpretation of study results and how these problems can be managed in clinical trials for human drugs, including drugs subject to licensing as biological products.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /